Company news
RenovoRx, Inc. news in 2025
RenovoRx, Inc.'s news releases, calls and decks from 2025, newest first.
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
December 11, 2025
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
December 1, 2025
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th
November 19, 2025
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update
November 13, 2025
RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD
November 6, 2025
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th
November 4, 2025
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4: 30 p.m. ET
October 27, 2025
RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD
October 9, 2025
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
September 25, 2025
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
September 11, 2025
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025
August 20, 2025
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
August 14, 2025
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
August 6, 2025
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
July 28, 2025
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4: 30 p.m. ET
July 14, 2025
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
May 15, 2025
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
May 14, 2025
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
May 6, 2025
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4: 30 p.m. ET
May 1, 2025
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial
April 29, 2025
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
April 16, 2025
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
April 4, 2025
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
April 1, 2025
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
March 28, 2025
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
March 26, 2025
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12: 00 p.m. ET
March 20, 2025
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
March 19, 2025
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
February 26, 2025
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
February 12, 2025
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
February 10, 2025
RenovoRx Announces Proposed Public Offering
February 5, 2025
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
February 5, 2025
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
January 26, 2025
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
January 7, 2025